Table 4. Clinical and Laboratory Safety and Tolerability Results (n = 3,201) .
| Number of patients with clinical adverse effects | Number of patients who discontinued due to adverse effects | |
|---|---|---|
| Hypoglycemia | 82 (2.5%) | 4 |
| Constipation | 29 (0.90%) | 7 |
| Dizziness | 25 (0.77%) | 4 |
| Eruption | 24 (0.74%) | 10 |
| Edema | 20 (0.62%) | 1 |
| Liver dysfunction | 19 (0.59%) | 5 |
| Abdominal distension | 18 (0.56%) | 4 |
| Diarrhea | 10 (0.31%) | 2 |
| Abdominal pain | 8 (0.25%) | 1 |
| Nausea and vomiting | 7 (0.22%) | 1 |
| Appetite loss | 3 (0.09%) | 0 |
| Others | 78 (2.4%) | 14 |
| Total | 323 (10.1%) | 53 |
*Data are number of subjects (%).